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Abstract
The neuraminidase (NA) inhibitors oseltamivir and zanamivir are the first-line of defense against potentially fatal variants of
influenza A pandemic strains. However, if resistant virus strains start to arise easily or at a high frequency, a new anti-
influenza strategy will be necessary. This study aimed to investigate if and to what extent NA inhibitor–resistant mutants
exist in the wild population of influenza A viruses that inhabit wild birds. NA sequences of all NA subtypes available from
5490 avian, 379 swine and 122 environmental isolates were extracted from NCBI databases. In addition, a dataset containing
230 virus isolates from mallard collected at Ottenby Bird Observatory (O ¨land, Sweden) was analyzed. Isolated NA RNA
fragments from Ottenby were transformed to cDNA by RT-PCR, which was followed by sequencing. The analysis of
genotypic profiles for NAs from both data sets in regard to antiviral resistance mutations was performed using
bioinformatics tools. All 6221 sequences were scanned for oseltamivir- (I117V, E119V, D198N, I222V, H274Y, R292K, N294S
and I314V) and zanamivir-related mutations (V116A, R118K, E119G/A/D, Q136K, D151E, R152K, R224K, E276D, R292K and
R371K). Of the sequences from the avian NCBI dataset, 132 (2.4%) carried at least one, or in two cases even two and three,
NA inhibitor resistance mutations. Swine and environmental isolates from the same data set had 18 (4.75%) and one (0.82%)
mutant, respectively, with at least one mutation. The Ottenby sequences carried at least one mutation in 15 cases (6.52%).
Therefore, resistant strains were more frequently found in Ottenby samples than in NCBI data sets. However, it is still
uncertain if these mutations are the result of natural variations in the viruses or if they are induced by the selective pressure
of xenobiotics (e.g., oseltamivir, zanamivir).
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Introduction
The scientific community has frequently expressed concern
about the potential of influenza A virus to evolve into novel strains
that can spread globally and induce pandemics [1–3]. These
warnings were proven justified 2009 when the world experienced
the last influenza A pandemic induced by strain H1N1, also
known as swine influenza or new influenza. Fortunately, the new
influenza was mild, as the viral infections in the majority of
infected humans did not end with serious complications [4,5]. All
influenza A viruses originate from the avian influenza A viruses
that naturally occur in waterfowl. The influenza genome encodes
11 proteins, of which one is non-structural. Avian influenza A is
classified according the presence of two membrane proteins,
hemagglutinin (HA) and neuraminidase (NA). There are 16 HA
and nine NA identified subtypes, and the majority of subtypes (96
of 144) are found in the mallard duck (Anas platyrhynchos), assumed
to be the major host and source of the influenza A viruses [6].
Vaccination is the most effective, cheapest and safest way to
protect the majority of a population against influenza A, but
vaccines can be difficult to rapidly produce in sufficient quantities
during influenza pandemics. Thus, many countries stockpile two
commercially available influenza A NA inhibitors, oseltamivir
(TamifluH; active substance after oseltamivir processing in the liver
is oseltamivir carboxylate (OC)) and zanamivir (RelenzaH), as the
main defenses against pandemic strains [7–9].
For both OC and zanamivir, high-level drug resistance is
conferred by single or multiple nucleotide changes in the NA gene,
as influenza A displays a high mutation rate and high viral
replication. Long-term seasonal use of amantadine, a previously
used antiviral of another class, has led to natural amantadine
resistance in epidemic H3N2 and H1N1 viruses. Thus, human
influenza A can develop resistance against both OC and zanamivir
[10–18]. As both inhibitors bind to the catalytic site of NA, cross-
resistance mutations are also found. Perhaps the most alarming
news is the emergence of drug-resistant strains of the H5N1
subtype that cause high rates of mortality in humans [19–21]. The
use of only OC and zanamivir as the first line of defense against
pandemic strains has been disputed, and the need for new
strategies or/and new antivirals has been proposed [22–24].
Furthermore, the use of both antivirals increases during seasonal
influenza, especially during a pandemic, which results in higher
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possible that wild birds (waterfowl) and, subsequently, influenza A
viruses may come in contact with sewage water enriched with the
antivirals. This may cause selection pressure on existing virus
populations, and as a consequence, resistant mutants may be
developed [25–29].
The aim of this study was to screen influenza A cDNA
sequences for resistance mutations against the two existing
neuraminidase inhibitors to determine the prevalence these
mutations in the wild bird population infected with influenza A.
In this investigation two data sets were used. The first data set was
collected between 2002 and 2008 at Ottenby Bird Observatory
and included 230 virus isolates from mallard. The second data set
was obtained from the NCBI database and contained all bird,
swine and environmental isolates of NAs of different subtypes.
Methods
Ethics Statement
Ethical approval for trapping, sampling, and keeping of birds
was obtained from the Malmo ¨/Lund Animal Research Ethics
Board (M139-03).
Virus sampling and q-PCR
Between 2005 and 2008 numerous cloacal samples from
mallard ducks (Anas platyrhynchos) were collected using the cotton
swab method. The sampling is a part of an ongoing surveillance at
Ottenby Bird Observatory on the Swedish island O ¨ land. The
swabs were placed in 2-ml tubes with virus transport media
[Hanks’ Balanced Salt Solution containing 0.5% lactalbumin,
10% glycerol, 200 U/ml penicillin, 200 mg/ml streptomycin,
100 U/ml polymyxin B sulfate, 250 mg/ml gentamicin, and
50 U/ml nystatin (ICN, Zoetermeer, Netherlands)] that were
immediately frozen at 270uC (at the latest, 30 min after
sampling). The 100 ml of virus transport media was used for
RNA extraction, which was performed using an EZ1 Virus Mini
Kit (QIAGEN, Germantown, MD, USA) and extraction Biorobot
EZ1 kit (QIAGEN), to yield a final volume of 75 ml of extracted
RNA [30].
The presence of virus in the samples was confirmed using one-
step q-PCR that targeted a conserved region of the avian influenza
A matrix gene. Extracted RNA (2 ml) was used as template in the
final reaction volume of 20 ml using a FastStart DNA Master
SYBR Green I kit (Roche Diagnostics GmbH, Roche Applied
Science, Mannheim, Germany). The amplification procedure was
performed in a LightCycler 1.5 (Roche Diagnostics GmbH) under
the following conditions: activation of polymerase for 10 min at
95uC and 43 cycles of 10 s at 95uC, 10 s at 60uC, and 10 s at
72uC. Finally, melting curve analysis was performed via a stepwise
temperature increase from 65uCt o9 5 uC, which identified the
melting temperature of the reaction product [30].
Virus growing and NA sequencing
All positive samples from q-PCR were grown in 11-day-old
pathogen-free chicken eggs (allantoic fluid). Each sample was
injected into two eggs and left at 37uC for 2 days, upon which the
allantoic fluid was removed by syringe. The presence of virus was
determined by hemagglutination assay using turkey erythrocytes.
HA subtyping was performed by hemagglutination inhibition
assay with subtype-specific hyperimmune rabbit sera [30].
The NA gene was sequenced to subtype the viruses. Total RNA
was extracted from all hemagglutination-positive samples (High
Pure RNA Isolation Kit; Roche Diagnostics GmbH, Germany)
[31]. RT-PCR was done either according Hoffman [32] (110
isolates) or according to Orozovic [31] (120 isolates). In both cases,
the PCR products were electrophoresed in 1.5% agarose and
visualized with ethidium bromide [31]. The bands of 1,400 bp
were cut out from the agarose gel, and the gel slices were purified
using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA,
USA). These 1,400-bp DNA fragments, representing NA genes,
were sequenced by Macrogen (Seoul, Korea). The obtained
sequence readings were assembled and processed using either
DNASTARH (DNASTAR, Inc., USA) or Vector NTI Advanced
version 10.3.0 (Invitrogen. Co., USA). The whole sequences were
aligned by BLAST, after which NA subtypes were identified [31].
NA sequences analysis
Published literature was researched for mutations connected to
both antivirals. NAs of all subtypes have eight conserved amino
acids involved in the contact with substrates as well as in the
function of the active site, and these are defined as catalytic
residues: R118, D151, R152, R224, E276, R292, R371, and
Y406. Ten additional amino acids, also well conserved, which are
so-called framework residues (E119, R156, W178, S179, D198,
1222, E227, E277, N294, and E425), are involved in stabilization
of the active site.
Nine mutations against OC (V116A, I117V, E119V, D198N,
I222V, H274Y, R292K, N294S and I314V) and 10 mutations
against zanamivir (V116A, R118K, E119G/A/D, Q136K,
D151E/G/N, R152K, R224K, E276D, R292K and R371K)
have been identified (N2 numbering; Table 1) [33–42]. Viruses
with mutations R292K and V116A show resistance to both
inhibitors. All mutations have been detected in human influenza A
strains, with the exception of D198, which is found in an influenza
B strain. As a reference, human N2 (accession number
CAD35677) from the NCBI database was used.
The alignments using ClustalW were performed in BioEdit
7.0.8.0 which was also used to scan all of the above-mentioned
mutations. The 230 mallard sequences from Ottenby as well as the
5490 avian, 379 swine and 122 environmental sequences obtained
from the NCBI database (Table 2) were included in the analyses.
Altogether, 6221 NA sequences were analyzed. The number of
mutations for each subtype is expressed as a proportion of the total
number analyzed sequences for that particular subtype (Table 2).
The proportions of mutations for avian isolates of both NCBI and
Ottenby sequences were pooled separately, which resulted in six
replicates in the NCBI group and five replicates in the Ottenby
group. To investigate if the proportion of mutants differed
between the two data sets, the unpaired t-test was performed
(Figure 1A).
Also all sequences from mallard isolates (795 sequences) were
extracted from the NCBI avian data set to form a new NCBI
mallard group. Another group was made of the same Ottenby
virus isolates from mallard. The frequency of wild-type isolates (no
mutations) and mutants was organized as a contingency table and
analyzed by chi-square test (Figure 1B). The null hypothesis was
that the proportion of mutants was the same in both sources of
sequences (NCBI vs. Ottenby).
Results
NCBI data set
The analyses of 5490 avian NCBI annotated sequences revealed
132 sequences carrying OC or zanamivir resistance mutations
(Table 2 and Table S1). Eight OC-related mutations (I117V,
E119V, D198N, I222V, H274Y, R292K, N294S and I314V) and
six zanamivir-related mutations (V116A, R118K, E119G/A/D,
R152K, R224K and R371K) were identified (Table 3). The
Influenza Antiviral Resistance in Wild Birds
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showed 57 (2.7%) and 55 (3.2%) mutants, respectively. The N5
subtype had the largest proportion of mutants (6.25%), while the
N4, N7 and N9 subtypes did not have any mutants (Table 2).
Subtype N1 showed one double mutant with I117V (OC-related)
and E119G/A/D (zanamivir-related) mutations, and subtype N2
had one triple mutant with the zanamivir-related R118K and
R152K and OC-related D198N mutations (Table 3). The most
common mutation in N1 was the OC-related I117V, while the
most common mutation for N2 was the OC-related I314V.
H274Y (the most frequent resistance mutation in human influenza
A) was seen in four isolates in N1 and one isolate in N2. Subtype
N3 had three types of mutations, of which the OC-related I222V,
which was found in five isolates, was the most frequent. Only one
type of mutation was found in the N5 or N6 subtype. D198N was
present in seven N5 isolates, and I222V was present in two N6
isolates. Subtype N8 had two different mutations: one V116A and
one I117V (Table 3).
In the swine isolates, most of the subtypes did not have any NA
inhibitor resistance mutations (i.e., subtypes N1, N3, N6, N8 and
N9). The mutations were found only in the N2 subtype, which had
18 isolates (8.87% of the N2 subtype and 4.75% of all subtypes)
with single mutations (Table 2 and Table S1). The majority of
isolates had the OC-related I314V mutation, while the zanamivir-
related Q136K mutation was found only in swine sample set
(Tables 1, 2, 3). In total, 122 isolates from the environment and
one N3 isolate (11.1% of subtype and 0.82 of total isolates; Table 2
and Table S1) had R152K (zanamivir-related) (Table 4).
Ottenby data set
Mutants were found in 15 of 230 (6.52%) NA sequences from
the Ottenby data set. Most of the mutants were found in the N6
subtype, which included six mutants (10.91%), followed by N1,
with four (10.26%), and N9, with three mutants (27.27%). The N3
and N5 subtypes had only one mutant (4.35% and 8.33%,
respectively) each, while the N2 and N8 subtypes did not show any
mutants. Subtypes N4 and N7 were not part of this collection of
sequences (Table 2). In the N1 subtype, I222V (OC-related) was
found in one isolate. One isolate (68556) had only an R118K
mutation, and isolate 68557 was a double mutant with R118K and
D151N mutations. The fourth isolate (79959) was triple mutant
with the zanamivir-related R118K, D151N and OC-related
D198N mutations. This isolate had an additional R156K change
in its sequence. However, this change is not related to resistance
[39]. The NCBI collection of avian sequences had 2 out of 5991
(0.03%) mutants with more than a single mutation, while in the
Ottenby collection the same type of mutants was found in 4 out of
230 (1.74%) isolates.
Mutants from both N3 and N5 subtypes had the R118K
inhibitor resistance change. In all mutants belonging to the N6
subtype, R152K and the subtype-conserved D198N mutation
were found. The OC-related mutation D198N has been observed
Table 1. Overview on published oseltamivir and zanamivir related mutations.
Mutation Inhibitor
1) Type of residue
2) Sensitivity in regard to NA subtype and acquisition
3)
Zanamivir Oseltamivir
V116A Z F (I) N1
a (R) N1
a
I117V O F (I) N1
a, (S) N1
b * (I) N1
a, (I) N1
b
R118K Z C (nr) N2
a (nr) N2
a
E119V O F (S) N2
a, (S) NB
a (R) N2
a, (R) NB
a, (R) N2
b
E119G Z F (R) NB
a, (R) N9
c, (R) NB
c (R) NB
a, (S) N9
c
E119A/D Z F (Nt/R) N2
a, (R/R) NB
a, (R/Nt) N1
a, (R/R) N2
c (Nt/S) N2
a, (R/R) NB
a, (R/Nt) N1
a, (I/S) N2
c
Q136K Z F (R) N1
a, c (S) N1
a, c
D151E/G/N Z F (S) N2
a, (S/S/S) N1
c (LR) N2
a, (S/S/S) N1
c
R152K Z C (S) NB
a, (S) N2
a, (R) NB
b (S) NB
a, (S) N2
a, (R) NB
b
D198N O F (R) NB
b (R) NB
b
I222V O F (S) N1
a (LR) N2
a, (S) N1
a
R224K Z C (R) N2
a (R) N2
a
H274Y Z F (S) N2
a, (S) N9
a, (S) N1
b (S) N2
a, (R) N9
a, (R) N1
b
E276D Z C (R) N2
a (LR) N2
a
R292K O/Z C (R) N2
a, (R) N2
c (R) N2
c, (R) N2
a, (R) N2
b
N294S O F (S) N1
a,( N t )N 2
b,( N t )N 1
b (R) N1
a, (LR) N2
b, (LR) N1
b
I314V O - (S) N1
b * (I) N1
b
R371K Z C (R) N2
a (R) N2
a
Mainly adopted from Ferraris and Lina [36].
1)Z - selected by zanamivir; O - selected by oseltamivir.
2)F - Framework residue; C - Catalytic residue.
3)Within bracket: R - resistant, I - intermediate, LR - low resistant, S - susceptible; nr - not recovered, Nt - not tested. Out of bracket: virus NA subtypes (N1 - 9 or B). Origin
of mutants:
a)reverse genetic,
b)In clinic,
c)In vitro;
*- mutations included in double mutant.
doi:10.1371/journal.pone.0016028.t001
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sequences from subtypes N6, N7 and N9 had this change as a
conserved feature. Two of the mutants from N9 carried one
R118K mutation, and one isolate was a double mutant with
R118K and D151N mutations. Furthermore, all isolates from this
subtype had the conserved D198N change (Table 5).
Statistical analyses
The unpaired t-test showed that the mean proportions of
mutations in the NCBI (2.66%) and Ottenby data sets (12.22%)
were different (p,0.05). Ottenby sequences had a higher
proportion of mutants than NCBI sequences. In the succeeding
analyses, frequencies of mutants within both data sets were
compared. Here, only sequences belonging to mallards from
NCBI data set (13.20% of all avian sequences) were included. The
chi-square test showed that the frequencies of mutants in the two
data sets (1.24% in NCBI and 6.52% in Ottenby) were different
(p,0.0001), i.e., mutants were more frequent in the Ottenby data
set.
Discussion
Resistance mutations related to subtypes
Resistance mutation patterns depend on the drug and the virus
subtype. Additionally, some subtypes (e.g., influenza N2) are more
sensitive to OC than to zanamivir, while the opposite is observed
with other subtypes (e.g., N1) [14,43].
In this study 6221 NA sequences were scanned for published
anti-OC and anti-zanamivir mutations (Table 1). When the
sequences from the NCBI database were compared with Ottenby
sequences, some differences emerged. The subtypes N4 and N7
were absent in the Ottenby sequence collection, but these subtypes
did not show mutations in the NCBI sequence collection. Subtypes
N2 and N8 from the NCBI data set had isolates with mutations,
while mutants were absent in the Ottenby N2 and N8 sequences.
This could be explained by the small number of sequences for
these subtypes in the Ottenby set (Table 2). In contrast, the N9
subtype collected at Ottenby had three mutants, while none was
seen in the NCBI date set. In the case of the N9 subtype, factors
such as host species difference and the location where the isolation
was carried out could be important. However, it is also possible
that the N9 subtype was more sensitive to selective forces, such as
immunity, natural NA inhibitors [44] or even different xenobiotics
distributed in the environment, including OC [25].
The largest proportion of mutants, 7 out of 112 (6.25%), in the
NCBI database was in the N5 subtype, which could indicate that
this subtype is the most prone to develop inhibitor resistance
mutations. However, six isolates included the same species and
were sampled at the same place (Table S1). These isolates were
Figure 1. Comparison of mutant proportions from the NCBI
and Ottenby databases carrying zanamivir and OC resistance
mutations. A) The mean percentages of six replicates from the NCBI
and five replicates from the Ottenby data set. All percentages represent
subtypes containing mutant virus isolates. Subtypes without mutants
are not represented in this analysis. The NCBI mean 6 SEM percentage
of mutants was 2.6660.865; N=6. The Ottenby mean 6 SEM
percentage of mutants was 12.2263.931; N=5. p,0.05, unpaired t-
test. B) Frequencies of wild-type isolates in the NCBI and Ottenby data
sets were 716 (98.76%) and 215 (93.48%) isolates, respectively.
Frequencies of mutant isolates in the NCBI and Ottenby data sets
were 9 (1.24%) and 15 (6.52%), respectively. In the NCBI data set, only
viruses isolated from mallard were counted. Bars represent the
percentage of wild-types and mutants in each data set. p,0.0001,
chi-squared test.
doi:10.1371/journal.pone.0016028.g001
Table 2. Summary of all virus isolates screened for antivirals
mutations.
Isolate source NA subtype
No. of
isolates (x)
No. of
mutants (y) % (y/x)
Avian N1 2133 57 2.67
N2 1737 55 3.17
N3 314 9 2.87
N4 73 0 0
N5 112 7 6.25
N6 379 2 0.53
N7 183 0 0
N8 409 2 0.49
N9 150 0 0
All 5490 132 2.40
Swine N1 169 0 0
N2 203 18 8.87
N3 4 0 0
N6 1 0 0
N7 1 0 0
N8 1 0 0
All 379 18 4.75
Environ. N1 26 0 0
N2 67 0 0
N3 9 1 11.11
N6 9 0 0
N8 10 0 0
N9 1 0 0
All 122 1 0.82
Ottenby N1 39 4 10.26
N2 77 0 0
N3 23 1 4.35
N5 12 1 8.33
N6 55 6 10.91
N8 13 0 0
N9 11 3 27,27
All 230 15 6.52
Total 6221 166 2,67
doi:10.1371/journal.pone.0016028.t002
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(same group of birds). Such relationships were observed in the
many of the sequences that showed mutant genotypes, and
information of this source is important when a detected mutation
pattern is being interpreted.
Comparison of the subtypes present in both data sets showed
that the Ottenby samples had a higher proportion of mutants than
the samples from the NCBI database (Figure 1A). Again, this could
simply have been an effect of a non-random grouping of data,
which was characteristic for both data sets. All Ottenby isolates
were collected between 2002 and 2008. The period when
mutation-carrying NCBI isolates were collected varied depending
on subtype. During 2002–2008, 93% and 84% of mutants were
collected for subtypes N1 and N2, respectively, in the NCBI
group. Only 25% of NCBI N3 isolates were from that period,
whereas none of the N5, N6 or N8 isolates was. However, in the
subsequent analyses, the time of data collection was ignored as a
factor that potentially influenced the quantity of mutants.
The lowest proportion of mutants from the Ottenby data set
was 4.35% for the N3 subtype, which was still higher than the
proportions of mutants from all other avian subtypes from the
NCBI data set, except for N5 (Table 2). The N5 subtype from
Ottenby had 8.33% mutants (1 out of 11), which was higher than
the same subtype from the NCBI data set. The highest proportion
of mutants from Ottenby isolates was found in the N9 subtype,
with 27.27% mutations (3 out of 11). The same subtype from the
NCBI database did not show any mutations. Another remarkable
difference between the two data sets was observed in the N6
Table 3. Overview of antivirals mutations virus isolates from
avian hosts (NCBI).
NA subtype Mutation
1) Type of residue
2) No.
N1 (o) I117V; (z) E119G/A/D F; F 1
(o) I117V F 36
(z) R118K C 1
(o) E119V F 1
(z) E119G/A/D F 2
(o) I222V F 5
(o) H274Y F 4
(o) R292K C 2
(o) N294S F 4
(z) S/R371K C 1
All 57
N2 (z) R118K; (z) R152K; (o)
D198N
C; C; F 1
(z) V116A F 1
(z) E119G/A/D F 5
(z) R152K C 2
(z) D198N F 1
(o) I222V F 1
(z) R224K C 2
(z) H274Y F 1
(o) N294S F 1
(o) I314V 40
All 55
N3 (z) V116A F 1
(o) I222V F 5
(o) L/I314V 3
All 9
N5 (o) D198N F 7
All 7
N6 (o) I222V F 2
All 2
N8 (z) V116A F 1
(o) I117V F 1
All 2
Total 132
1)(z) - zanamivir related mutations; (o) - OC related mutation.
2)C - catalytic residue; F - framework residue.
doi:10.1371/journal.pone.0016028.t003
Table 4. Overview of antivirals mutations in virus isolates
from swine and environment (NCBI).
NA subtype Mutation
1) Type of residue
2) No.
swine N2 (z) E119G/A/D F 1
(z) Q136K 1
(o) D198N F 1
(z) R224K C 1
(o) I314V 14
All 18
environ. N3 (z) R152K C 1
All 1
Total 19
1)(z) - zanamivir related mutations; (o) - OC related mutation.
2)C - catalytic residue; F - framework residue.
doi:10.1371/journal.pone.0016028.t004
Table 5. Overview of antivirals mutations in virus isolates
from avian hosts (Ottenby).
NA subtype Mutation
1) Type of residue
2) No.
N1 (z) R118K; (z) D151N; (o)
D198N
C; C; F 1
(z) R118K; (z) D151N C; C 1
(z) R118K C 1
(o) I222V F 1
All 4
N3 (z) R118K C 1
All 1
N5 (z) R118K; (z) R152K; (o)
D198K
C; C; F 1
All 1
N6 (z) R152K C 6
All 6
N9 (z) R118K C 2
(z) R118K; (z) D151N C; C 1
All 3
Total 15
1)(z) - zanamivir related mutations; (o) - OC related mutation.
2)C - catalytic residue; F - framework residue.
doi:10.1371/journal.pone.0016028.t005
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higher in the Ottenby than the NCBI data set (Table 2).
These results indicate an increase of mutant frequency in the
population of avian influenza A viruses in mallard duck from
Ottenby. The reason for this can only be speculated. Given the
migratory routes of mallard duck that include many populated
areas in northern and western Europe [45,46], it is appropriate to
assume that mallards and consequently viruses could encounter
water-borne OC or zanamivir more frequently than viruses in
avian species collected from the NCBI data set. The possibility for
recombination between avian and human virus strains already
carrying mutations in the NA gene cannot be ruled out [3].
In swine, only the N2 subtype sequences contained mutants
(8.87%), while in viruses isolated from the environment, only one
mutant in the N3 subtype was observed. Among swine mutants,
seven belong to H3N2 virus subtype, five to H1N2 and six to
H9N2 virus subtype (Table S1). Two of the NA mutants (Q136K
and D198N) from H3N2 subtypes have sequence similarity with
human N2 which indicates that they probably originate from
humans. The rest of NAs of H3N2 and all NAs from H1N1 virus
subtype are most similar to swine N2 indicating origin from the
same organism. On the other hand each NA mutant from H9N2
subtype shows similarity with NA isolated from chicken i.e. duck
(A/Duck/Hong Kong/Y280/97) which implies avian origin.
Adaptation of avian [47,48] or human [49] N2 to the new host
(swine) that led to changes in the swine N2 subtype might have
provided conditions favoring a more frequent occurrence of
antiviral resistance genotypes than in the avian N2 subtype
(Table 2) [3,5,50,51].
Regarding mutants isolated from environmental samples, only
one with the zanamivir- related R152K mutation was found,
dating from 2004 (Table 4 and Table S1). Altogether, 122
environmental NA sequences are available in the NCBI database,
which may indicate difficulties in recovering virus genomic RNA
from environmental samples or restricted efforts in doing so. The
limited number of sequences from this analysis might explain why
there were not more mutants within this group of sequences. The
R152K mutation also occurred in the N2 subtype from the NCBI
data set, as well as in the N6 subtype from the Ottenby data set.
NA RNA from the environmental sample originating from
Canada (Table S1) had the greatest similarity with chicken NA
RNA that was also isolated in Canada. It is likely that the NA
isolated from the environment originated from local poultry farms.
Undetected resistance mutations in the study
Scanning of all avian NA sequences from the NCBI database
showed that all known OC-related mutations were present in this
data set [36,52]. On the contrary, the zanamivir-related mutations
Q136K [42], D151E and E276D [36,40] were not observed in the
same data set (Table 3).
The measured concentration maxima (Cmax) of OC [53,54]
and zanamivir [55] in the blood plasma can vary in the ranges of
1.4–1.9 mM and 0.05–0.43 mM, respectively. On the other hand,
concentrations of both inhibitors that induce mutations in vitro are
well above 1.0 mM [41,56]. The peak concentration of OC in two
studies from Japan was reportedly 0.001 mM [28,29], but in
studies from the UK and U.S., it was predicted to be as high as
0.05 mM and 0.1 mM, respectively [27]. Thus, it is apparent that
in cases of induced antiviral resistance, the concentrations of NA
inhibitors in vitro are well above the values detected or predicted in
the environment. Even if OC or zanamivir had bioaccumulated in
the waterfowl, it is likely that their concentrations would be much
lower than OC concentrations known to select for resistant virus
strains.
To summarize, a possible explanation for the lack of Q136K,
D151E and E276D mutations in avian influenza A could be that
virus variants with such changes in the NA gene are not part of the
natural variation. However, even if they were, it is probable that
selection pressure in the form of competition with other virus
variants reduces the fitness of the virus so severely that these
mutations do not develop.
Detected primary and secondary mutations in this study
It has long been thought that reductions in viral fitness
conferred by NA inhibitor resistance mutations would prevent
transmission and the spread of resistance. However, recently NA
inhibitor resistance has become apparent and has gradually spread
amongst circulating seasonal influenza viruses worldwide. This
could occur during prolonged treatment in, e.g., immunocom-
promised patients. Therefore, ‘‘permissive’’ secondary mutations
emerge that compensate for the reduced fitness of the primary NA
inhibitor resistance mutations [16,18,57].
In the NCBI data set. When the mutations found in the N1
subtype were categorized relative to two inhibitors (R292K
excluded), 96% of all mutations were OC-related. Only one
double mutant, with I117V and E119A mutations, was found in
the same subtype. This mutant probably did not show a reduction
in fitness, as it persisted in competition with other N1 versions that
lacked those changes. The OC-related mutation I117V was the
most frequent mutation, and it accounted for 63% of all mutants.
It has been detected in NA of an H5N1 virus strain (A/Chicken/
Indonesia/Wates/77/2005) that also had the I314V mutation,
which made this strain a OC resistant double mutant I117V/
I314V (Table 1) [34]. On the background of human strain H1N1
A/WSN/33, mutation I117V alone is sensitive to OC but weakly
resistant to the NA inhibitor A-315675 [58]. The capability of
I117V to reduce viral sensitivity to NA antivirals would probably
depend on the presence and identity of secondary mutations [34].
I117V was, in 23 of 36 cases (64%), isolated at the same time, at
the same place and from the same species (open-billed stork),
which indicated that the same group of birds has been infected
with the same virus subtype. The next most frequent mutations in
the N1 subtype were I222V, H274Y and N294S (Table 3). I222V
has been detected by reverse genetics (RG) in both N1 and N2
subtype, while H274Y and N294S have been found in human
clinical isolates in the N1 and in the N1 and N2 subtypes,
respectively (Table 1) [36]. The highly OC-resistant mutation
H274Y is the most frequent mutation in human isolates of H1N1
viruses [16,18] and has even been discovered in highly pathogenic
avian H5N1 strains [20]. The ability of avian influenza A viruses
to carry OC-resistant mutations was revealed in this sequence
screening. This implies that these viruses possess enough fitness to
cope with all the challenges imposed on them by the environments
(different hosts, different types of open waters) in which they exist.
Of all mutations in the N2 subtype, the OC-related I314V
mutation was dominant (73%) compared to the total proportion of
all mutations (Table 3). This mutation has not been reported in the
literature as a single mutation but only as a paired one with I117V
[34]. Therefore, it is not clear whether it could alone influence
changes in susceptibility to NA inhibitors. Still, its presence in
viruses of wild populations could be potentially harmful if such
viruses obtain additional mutation(s). One triple mutant was found
within N2 sequences, carrying the R118K, R152K and D198N
mutations. In this triple mutant, as in the case of the double N1
mutant, the fitness did not appear to be reduced dramatically, and
it is possible that in both cases these changes in sequence could be
compensatory regarding viral fitness [33].
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specific for the N1 subtype, while V116A, R152K, R224K, and
I314V were specific for the N2 subtype (Table 3). There were also
differences in the frequencies of some mutations. I222V, H274Y
and N294S were found in a higher number in the N1 subtype,
while E119G/A/D was more frequent in the N2 subtype. The
majority of mutations in the N1 subtype were OC-related, while
most mutations in the N2 subtype were zanamivir-related
(provided that I314V was not treated as a resistance-related
mutation). In regards to the most frequent mutations for N1
(I117V) and N2 (I314V), it appears that they could be simply a
natural form of NA, i.e., they were neutral mutations. The same
was true for all N6, N7 and N9 subtype viruses that had D198N,
which is otherwise related to OC resistance in influenza B viruses
isolated in the clinic [36].
Of all sequences tested, only the avian N3 subtype had one
isolate with the zanamivir-related V116A mutation [35,58], and
the rest of the mutations were I222V and S/I314V (Table 3). The
N5 and N6 subtypes each had only one type of mutation.
Moreover, the N6 and N8 subtypes had only two isolates with
mutations. However, the low number of NA sequences for these
subtypes compared to N1 and N2 (Table 2) made it difficult to
draw any firm conclusions on the frequency and type of mutations.
Only five types of mutations were detected within swine NA
sequences. The zanamivir-related Q136K mutation was only
found here (Table 4). I314V was the most frequent mutation, and
if its frequency is compared to frequency of avian N2, where the
same mutation was also prevalent (Table 3), then this NA variant
might have originated from avian NA, where it was likely a part of
a normal gene pool variation for the N2 subtype. Furthermore, if
I314V was ignored in both the avian and swine N2 subtype, then it
appears that the rest of the mutations constituted 0.9% and 2.0%
of the avian and swine N2 subtype populations, respectively.
According to this, the swine N2 subtype was more receptive for
antiviral resistance mutations than the avian N2 subtype.
In the Ottenby data set. In sequence collection from
Ottenby (Table 5), only the N1 subtype had different mutation
types, i.e., R118K, D151N, R156K, D198N and I222V. The rest
of the subtypes had either the zanamivir-related R118K or R152K
mutations only. The zanamivir-related mutation R118K obtained
only by RG has not been possible to analyze by enzyme assay due
to a complete lack of NA activity (Table 1) [40]. In the Ottenby
data set R118K was present in all subtypes except in N6. In the N9
subtype from Ottenby, R118K showed the highest frequency of all
mutations in all subtypes from both data sets. Interestingly virus
H3N2 with the R118K mutation has been difficult to isolate from
in vitro culture [40], but in the Ottenby set such mutants existed as
a part of the natural population in mallard. The N1 subtype had
one double and one triple mutant, with R118K/D151N and
R118K/D151N/D198N mutations, respectively. The triple
mutant had an additional mutation, R156K, but that mutation
is not considered resistance-related. The presence of multiple
mutations could be considered secondary compensatory mutations
that work in synergy together with the first resistance mutation,
which usually reduces the fitness of the virus. In the N1 subtype,
half of the mutants carried multiple changes in NA sequences. If
the relationship between the mutation frequencies and non-
mutant frequencies were counted, then N1 had 18.00% of
mutations instead of 10.26%. Such a high mutation rate could
be an indication of the existence of additional selection forces not
previously involved.
Comparisons of N1 mutations from both Ottenby and NCBI
revealed some interesting details (Tables 1, 2 and 4). For example,
the proportionofR118KmutationsinOttenbywas7.7%ofthetotal
numberanalyzedsequencesforN1subtype,whilethecorresponding
mutation rate for the NCBI data set was only 0.04% of total
sequences for the same subtype (Table 2). Two R118K mutants
originated from successive years (2007–2008), which could indicate
that this mutation was established in the wild virus population.
It is tempting to speculate that the wild virus population of the
N1 subtype has gone through evolutionary changes driven by
selective forces (antigenic drift, natural NA inhibitors or xenobi-
otics) and that it is not driven by evolutionary fidelity. If one such
virus population carries such a resistance mutation, it could
potentially be harmful if it obtains other resistance-related genetic
shifts. Thus, contact between a wild bird virus population and a
human strain is the only step necessary in this scenario. Such an
event is possible either via direct transmission from birds to
humans or via transmission involving a mixing vessel, such as pigs
[3]. Furthermore, the mutation R118K (Table 5) has been
experimentally induced (RG) only in the N2 subtype [36], and its
instability seriously impacts viral fitness [40]. R118K was
associated with N1, N3, N5 and N9 subtypes in the Ottenby data
set. It could be that the spread of R118K was a result of a
recombination event, i.e., R118K was transmitted from one NA
subtype to the other. This would be possible when more virus
strains infect the same host simultaneously, in this case the
mallards. Mallards are birds that gather in high numbers at
Ottenby. Still, not all of the birds are infected with the same virus
strain at the same time, which significantly increases the chance
that they could be infected with different virus strains.
In the Ottenby data set, besides the D198N found in the N1
triple mutant, I222V was another OC-related mutation. This
mutation has been obtained by RG [36,38] involving the N1 and
N2 subtypes (Table 1), which did not show a resistant phenotype.
However, in combination with mutation H274Y, its IC50
increased almost 2000 times for one H5N1 strain [41]. The
mutation I222V was detected in one (2.56%) isolate in the N1
subtype from the Ottenby date as well as in five (0.23%) and one
(0.06%) isolates in the N1 and N2 subtypes from the NCBI data,
respectively. Thus, this ‘‘permissive and secondary’’ mutation was
found in a much higher proportion in the Ottenby set.
Mutation D151Nwaspresentintwo isolatesfrom the N1subtype
as the second mutation besides R118K. This mutation was, until
recently, only associated with RG experiments involving the human
N2 subtype, where it showed resistance against zanamivir (Table 1)
[36]. In a recent publication D151N was found alone or together
with H274Y in human N1 isolates [38]. It did not influence
sensitivity to anyinhibitorsalone,butincombination with H274Y it
increased resistance to OC and to another NA inhibitor, peramivir.
D151N can also result as adaptation to a new host, i.e., MDCK
cells. The isolate 79959, with R118K and D151N mutations, also
has R156K and D198N mutations. R156K is not related to
inhibitor resistance (and therefore is not shown in Table 3 or 4), but
D198N has been detected in influenza B isolates as an OC-
resistancemutation [36]. D198N was also found in one avian isolate
of N2 and all avian isolates of N5 from the NCBI data set (Table 3).
The occurrence of D198N could be the result of either a
compensatory change to an already present primary resistance
mutation that reduced fitness or the result of a recombination with
virus subtypes that had it as a conserved residue.
The N3 and N5 subtypes had the R118K mutation as the only
mutation in the Ottenby set. The R118K mutation was not found
in N3 from the NCBI data set. However, in the NCBI data set this
mutation was detected in two avian isolates: one from the N1 and
one from the N2 subtype (Tables 2 and 4). A similar trend was
observed even in the case of the N5 subtype. In the NCBI data set
the N5 subtype exclusively had the OC-related D198N mutation,
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related R118K mutation.
The N6 subtype had six mutants (10.91%) with the catalytic
residue change R152K. No such mutation was detected in the
same subtype in the NCBI data set, which had two mutants
(0.53%) with I222V (Tables 1 and 2). Interestingly the zanamivir-
related mutation R152K, found in the bird NCBI data collection,
was characteristic for the N2 subtype only, comprising 0.12% of
the total number of sequences for the subtype.
SubtypeN9fromthe NCBI dataset didnot have anymutation at
all. However, the same subtype from the Ottenby data set had the
highest proportion of mutants (3 out of 11; 27.27%) relative to all
subtypes of both data sets (Table 2). These three mutants had the
same R118K change, which has been observed by RG on the N2
subtype [40]. However, a residue switch in one subtype does not
necessarilyrelatetoNAinhibitorresistanceinanothersubtype.Still,
this N9 catalytic residue change could indicate (as already
mentioned in the case of the N1 subtype) that certain forces select
for the accumulation of such resistance mutations in the NA gene.
The Ottenby isolates carrying the catalytic residue change
R118K (N1, N3, N5 and N9) or R152K (N5 and N6) would be
interesting to study in NA enzymatic inhibition assays, and such
research is currently in progress in our laboratory. R118K is
especially interesting because RG viruses carrying this mutation do
not propagate well. There is also the possibility that these mutations
were obtained as an adaptation in chicken eggs. However, it should
be emphasized that almost all virus isolates in our study went
through only one passage, so this event was less likely.
Statistical analyses
NA subtypes that did not have any mutants were excluded from
the total number of sequences. The test showed (Figure 1A) that
the proportion of mutants was different between those two data
sets (p,0.05). This analysis included all avian species from the
NCBI data set, and it provided insight into how mean percentages
of virus mutants were related in a more general fashion within
these two data sets.
Within the analyzed NCBI sequences, the majority of isolates
with mutations did not come from waterfowl (ducks, geese and
swans) but from chicken, stork, turkey, quail, tern and herring.
Ottenby samples were exclusively isolated from mallards.
Transmission of influenza A from its natural host, mallard [59],
to another bird species, such as chicken [51], or to another animal
species in general [1,3,4,50] could have led to changes in the NA
gene that were the result of an adaptation to a new host. Thus, in
order to avoid influence of NA gene changes arisen due to
adaptation to a new host, all sequences from each NA subtype
found only in mallards were extracted from NCBI data set and
compared with Ottenby data set. The two data sets were put in a
contingency table and analyzed by chi-squared test (Figure 1B),
which gave the same result as the unpaired t-test. The frequency of
mutations found in the Ottenby data set was higher than in the
NCBI data set (p,0.001).
In summary, antiviral resistance–related mutations already exist
in populations of avian influenza A viruses isolated from their
natural hosts, i.e., mallard duck, other waterfowl as well as
domestic poultry, and domestic swine. Therefore, several questions
come into focus.
The first question is whether virus strains carrying resistance
mutations are natural fluctuations of different virus versions [60].
Forces triggering such changes could be immune defense, natural
NA inhibitors and adaptation to diverse transmission directions.
Additionally, these changes could be a consequence of regulation
of the balance between HA and NA activities subsequent to
changes in HA affinity towards its cell receptor. Such an
adaptation of NA as a response to changes in HA could lead to
NA inhibitor resistance [61].
The second question is related to the need to investigate whether
those mutations actually reduce NA sensibility to inhibitors. They
could, in the light of differences in amino acids between avian and
human virus strains, be neutral, i.e., they might not reduce
sensibility to NA inhibitors. It would be interesting to investigate
the naturally produced mutants by NA enzymatic inhibition assays
to find out if they behave in the same way as their human counter-
parts. Such studies are currently in progress in our laboratory.
The third question concerns the source of transmissibility and
antigenic shift of influenza A, which could be an important issue
facing the next influenza outbreak. It is essential to investigate the
transmission potential of those avian mutant strains to humans, as
these strains might already be equipped with resistance against the
currently used inhibitors OC and zanamivir. Therefore, the
strategy of stockpiling influenza NA antivirals as a first line of
defense against new pandemic strains could be endangered. In
another study by us, preliminary results indicate that H1N1-
infected mallards exposed to environmental concentrations of OC
can develop the H274Y mutation (unpublished data).
The fourth and final question deals with the possibility of an
increased frequency of NA mutations in the wild populations of
viruses, as well as the emergence of novel and so far dormant
subtypes (N9) in potentially harmful virus strains. Based on the
results from the Ottenby data set, this possibility is not unreasonable
(Figure 1A–B). It appears that certain selective forces have pushed
the virus towards phenotypes that could be better equipped to infect
a larger number of hosts. The threat of antiviral resistance in future
influenza outbreaks warrants further exploration of alternative
therapeutic strategies, e.g., new classes of drugs used in combination
therapy with NA inhibitors [22,23] or alternative technologies for
faster production of influenza vaccine [62].
Supporting Information
Table S1 List with mutants from NCBI dataset includ-
ing protein ID, subtype, mutation, mutation sequence
domain and strain name.
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